Spots Global Cancer Trial Database for cd20
Every month we try and update this database with for cd20 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | NCT05040906 | Recruiting | H02+CHOP Rituxan +CHOP | 18 Years - 75 Years | Shandong New Time Pharmaceutical Co., LTD | |
| Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma | NCT00220285 | Non-Hodgkin's L... Lymphoma, B-Cel... Lymphoma, Low-G... | Zevalin (SH L 7... Zevalin (SH L 7... | 20 Years - 74 Years | Bayer | |
| Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP | NCT02983097 | Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Burkitt Lymphom... Aggressive Marg... | Rituximab Cisplatin Carboplatin Dexamethasone Cytarabine Lenalidomide PegFilgrastim peripheral stem... | 18 Years - 70 Years | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia | NCT01059786 | Hairy Cell Leuk... | Pentostatin Rituximab Bendamustine Acetaminophen Diphenhydramine Epinephrine Antihistamines Corticosteroids Bronchodilators Intravenous (IV... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies | NCT04156178 | B Cell Lymphoma B Cell Leukemia | CD20-CD19 cCAR ... | - | iCell Gene Therapeutics | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | NCT05737628 | Lymphoma | BYON4228 + Ritu... | 18 Years - | Byondis B.V. | |
| Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | NCT02715843 | Non-Hodgkin's B... | MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B | NCT00926757 | Non Hodgkin's L... Hepatitis B | Entecavir proph... Therapeutic ent... | 16 Years - | Taipei Veterans General Hospital, Taiwan | |
| Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas | NCT01788189 | B-cell Lymphoma | Lenalidomide | 18 Years - | University Hospital, Essen | |
| Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02556346 | Chronic B-cell ... Small Lymphocyt... | MT-3724 MT-3724 MT-3724 MT-3724 MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies | NCT03125577 | B-cell Malignan... | 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... | 6 Months - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | NCT05169489 | Diffuse Large B... | bbT369 | 18 Years - | 2seventy bio | |
| Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | NCT02715843 | Non-Hodgkin's B... | MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated | NCT03888105 | B-cell Non-Hodg... | Odronextamab | 18 Years - | Regeneron Pharmaceuticals | |
| HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | NCT00394836 | Lymphoma, Folli... | Ofatumumab Ofatumumab | 18 Years - | GlaxoSmithKline | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU | NCT06116110 | Non Hodgkin Lym... | Long-term Follo... | 18 Years - | Miltenyi Biomedicine GmbH | |
| Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia | NCT01059786 | Hairy Cell Leuk... | Pentostatin Rituximab Bendamustine Acetaminophen Diphenhydramine Epinephrine Antihistamines Corticosteroids Bronchodilators Intravenous (IV... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) | NCT01419665 | Follicular Lymp... | GP2013 rituximab | 18 Years - | Sandoz | |
| GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) | NCT01419665 | Follicular Lymp... | GP2013 rituximab | 18 Years - | Sandoz | |
| Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL | NCT03271515 | Leukemia Lymphoma | anti-CD19 anti-... | 18 Years - 70 Years | Beijing Doing Biomedical Co., Ltd. | |
| CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) | NCT06002659 | B-cell Lymphoma | CAR20(NAP)-T Cyclophosphamid... Fludarabine | - | Uppsala University | |
| Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas | NCT01788189 | B-cell Lymphoma | Lenalidomide | 18 Years - | University Hospital, Essen | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation | NCT01809847 | Chronic Lymphat... | Ofatumumab | 56 Years - | Technische Universität Dresden | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | NCT05737628 | Lymphoma | BYON4228 + Ritu... | 18 Years - | Byondis B.V. | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | NCT05040906 | Recruiting | H02+CHOP Rituxan +CHOP | 18 Years - 75 Years | Shandong New Time Pharmaceutical Co., LTD | |
| Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B | NCT00926757 | Non Hodgkin's L... Hepatitis B | Entecavir proph... Therapeutic ent... | 16 Years - | Taipei Veterans General Hospital, Taiwan | |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | NCT05169489 | Diffuse Large B... | bbT369 | 18 Years - | 2seventy bio | |
| Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02556346 | Chronic B-cell ... Small Lymphocyt... | MT-3724 MT-3724 MT-3724 MT-3724 MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | NCT00394836 | Lymphoma, Folli... | Ofatumumab Ofatumumab | 18 Years - | GlaxoSmithKline | |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated | NCT03888105 | B-cell Non-Hodg... | Odronextamab | 18 Years - | Regeneron Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
